Board of Directors


Bruce Booth, DPhil, is a partner in the life sciences group and focuses on the discovery and development of novel therapeutics.

Since joining Atlas in 2005, Bruce has been involved in the founding and funding a number of innovative companies with a particular focus on capital efficient models for drug R&D. He currently serves on the board of miRagen Therapeutics (co-founder), Zafgen, Bicycle Therapeutics, Nimbus Discovery (co-founder), Rodin Therapeutics (co-founder), and several other seed-stage biotech companies. Previously, Bruce served on the boards of past Atlas companies Avila Therapeutics (acquired by Celgene), Stromedix (acquired by Biogen), Prestwick (acquired by Biovail), and Proprius (acquired by Cypress Biosciences), among others.

Prior to joining Atlas, Bruce was an investor with Caxton Health Holdings and before that, a consultant at McKinsey & Company, a global strategic management consulting firm. While at McKinsey, he worked extensively with pharmaceutical and biotechnology firms to address R&D productivity issues, as well as portfolio management, new product commercialization, and business development.

Bruce currently serves on UCB Pharma’s Scientific Advisory Board, as well as Pfizer’s Healthcare “R&D 2020″ Innovation Think Tank, and participates on several other advisory boards for pharmaceutical companies and academic medical centers. Bruce is also a trustee of the New York Academy of Medicine. He recently joined the Science Exchange’s Reproducibility Initiative Advisory Board, focused on improving the reliability of translational research.

Bruce writes about life science venture capital topics at his blog, which is also syndicated with Forbes. He has published numerous scientific papers and has authored various biotech venture capital review articles, including several in Nature Biotechnology. In 2010, Bruce was named to Boston Business Journal’s “40 under 40” list.

As a British Marshall Scholar, Bruce received a D.Phil. (Ph.D.) in molecular immunology from Oxford University. His work focused on the study of HIV and tumor immune responses. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.